Compare Quest Diagnostics Inc (DGX) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs STMicroelectronics NV — how do they compare? Quest Diagnostics Inc trades at $237.22 (market cap $26.21B), while STMicroelectronics NV trades at $55.99 (market cap $49.21B). The key difference: STMicroelectronics NV is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | STM | |
|---|---|---|
Market Cap | $26.21B | $49.21B |
Sector | Health | Financials |
52-Week High | $238.50 | $79.91 |
52-Week Low | $173.49 | $21.20 |
Enterprise Value | $31.97B | $47.21B |
Dividend Yield | 1.45% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
STM trades at $54.35, down 3.12% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.31, beating expectations, but faces declining revenue and net income margins. Analyst consensus is a Buy with a $74.63 price target, supported by strong AI data center growth prospects highlighted in recent earnings calls (Zacks Investment Research, 2026-07-24).
Outlook is mixed; growth catalysts in AI and automotive sectors offer upside potential, but high P/E of 107.92 and recent earnings misses pose valuation and execution risks. Cash flow improved in 2025, yet profitability remains pressured. The stock's near-term direction hinges on Q3 2026 results and demand trends in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
